Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program

Blood

Volumn 95, Issue 7, 2000, Pages 2219-2225

  McGlave, Philip B ^a   Shu, Xiao Ou ^b   Wen, Wanqing ^b   Anasetti, Claudio ^b   Nademanee, Auayporn ^b   Champlin, Richard ^b   Antin, Joseph H ^b   Kernan, Nancy A ^b   King, Roberta ^b   Weisdorf, Daniel J ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DONOR; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN RELATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 12944309759     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2219     Document Type: Article

References (49)

1. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254.
2. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616.
3. Bhatia R, Forman SJ. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;12:151.
4. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104: 155.
5. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202.
6. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313: 765.
7. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197.
8. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864.
9. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339:1186.
10. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593.
11. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. The National Marrow Donor Program: how it works, accomplishments to date. Oncology. 1989;3:63.
12. Perkins HA, Hansen JH, The U.S. National Marrow Donor Program, Am J Ped Hematol Oncol. 1994;16:30.
13. National Marrow Donor Program Standards Committee. Standards of the National Marrow Donor Program. Transfus Med Rev. 1993;33:172.
14. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases [erratum in Blood. 1990;76:654]. Blood. 1990;75:1728.
15. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543.
16. Bodmer JG, Marsh SGE, Albert ED, et al. Nomenclature for factors of the HLA system. Hum Immunol. 1994;41:1.
17. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606.
18. Devergie A, Apperley JF, Labopin M, et al for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Bone Marrow Transplant. 1997;20:11.
19. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994; 83:1980.
20. Spencer A, Szydlo RM, Brookes PA, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood. 1995;86:3590.
21. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962.
22. Beatty PG, Ash R, Hows JM, McGlave PB. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant. 1989;4:287.
23. Mackinnon S, Hows JM, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol. 1990;18:421.
24. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163.
27. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187.
28. Petersdorf EW, Hurley C, Dupont B, et al for the US NMDP. Analysis of 328 marrow transplants for the treatment of chronic myeloid leukemia from unrelated donors facilitated by the US National Marrow Donor Program (NMDP). effect of HLA-DRB1 allele disparity on clinical outcome. Blood. 1996;88(suppl):268a.
29. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234.
30. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897.
31. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634.
32. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036.
33. Devergie A, Biaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85:2263.
34. Davies SM, Ramsay NKC, Haake RJ, et al. Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant. 1994;13:51.
35. Papadakis V, MacKinnon S, Kernan NA. Differential effect of pre-transplant cytoreduction on recovery of day 0 host circulating cells. Bone Marrow Transplant. 1994;14:623.
36. Petersdort EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89:1818.
37. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79.
38. Sasazuki T, Juji T, Morishima Y, et al for the Japan Marrow Donor Program. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177.
39. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA Class I and II alleles in the donor and recipient. Blood. 1998;92:3515.
40. Beatry PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood. 1993;81:249.
41. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A. 1996;93:15358.
42. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood. 1995;86:1228.
43. Nachbaur D, Schwaighofer H, Petersen F, et al. Successful second transplant from an HLA-identical unrelated donor after graft rejection in a patient with chronic myelogenous leukemia. Transplantation. 1994;57:478.
44. Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14:73.
45. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant. 1996;17:213.
46. Gale RP, Hehlmann R, Zhang M-J, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood. 1998;91:1810.
47. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myeloid leukemia: a decision analysis. Ann Intern Med. 1997;127:1080.
48. Guilhot F, Chatang C, Michallet M, et al for the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukamia. N Engl J Med. 1997;337:223.
49. Morton AJ, Gooley T, Hansen JA, et al. Association between pre-transplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394.